About

Donald A. Wuchterl became an Abeona director on April 14, 2021 and serves on the Nominating and Corporate Governance Committee and the Audit Committee. Since August 2022 he has provided Chemistry, Manufacturing and Controls (CMC) and Technical Operations executive-leadership consulting to pre-clinical gene therapy companies. From April 2021 to August 2022 he was Senior Vice President and Chief Manufacturing Officer at T-knife Therapeutics, and from 2016 to 2021 he was Senior Vice President, Technical Operations and Quality at Audentes Therapeutics (an Astellas company). From 2012 to 2016 he was Senior Vice President and Chief Operating Officer at Cytovance Biologics, and earlier held roles at Dendreon, Shire HGT, Amgen, Biogen Idec and Roche. He holds a B.S. in Business Administration from Colorado Technical University and an MBA from Fitchburg State University.

Roles

Abeona Therapeutics Inc.
Director · Current role
April 2021–present
Independent consultant (CMC and Technical Operations)
Executive-leadership consulting to pre-clinical gene therapy companies
August 2022 - present
T-knife Therapeutics
SVP and Chief Manufacturing Officer
April 2021 - August 2022
Audentes Therapeutics (an Astellas company)
SVP, Technical Operations and Quality
2016 - 2021
Cytovance Biologics
SVP and Chief Operating Officer
2012 - 2016
Dendreon / Shire HGT / Amgen / Biogen Idec / Roche
Positions of increasing responsibility

Director Compensation

FY 2025
Fees earned or paid in cash
$67,500
ComponentAnnual board fee plus committee and committee-chair fees earned in 2025, paid quarterly
Stock awards
$200,000
ComponentRestricted stock award for 2025 Board service (36,101 shares granted January 31, 2025 at $5.54, ASC 718 grant-date fair value); vests one year after grant
Total
$267,500

Also at Abeona Therapeutics Inc.

Related

See how VectorShift works for your firm

Request Demo